Court Report - October 21, 2012

[author: Sherri Oslick]

Gavel About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

Eisai R & D Management Co., Ltd. v. Honorable David J. Kappos
1:12-cv-01138; filed October 12, 2012 in the Eastern District of Virginia

Review and correction of the patent term adjustment calculation made by the U.S. Patent and Trademark Office for U.S. Patent No. 8,158,620 ("Fused Aminodihydrothiazine Derivatives," issued April 17, 2012).  View the complaint here.

Genetic Technologies Ltd. v. Genetics & IVF Institute, Inc.
3:12-cv-00724; filed October 11, 2012 in the Eastern District of Virginia

Infringement of U.S. Patent No. 5,612,179 ("Intron Sequence Analysis Method for Detection of Adjacent Locus Alleles as Haplotypes," issued March 18, 1997) based on Genetics & IVF Institute's manufacture, use, sale, and offer for sale of preimplantation genetic diagnosis services.  View the complaint here.

Purdue Pharma LP et al. v. Sandoz Inc.
1:12-cv-07582; filed October 10, 2012 in the Southern District of New York

• Plaintiffs:  Purdue Pharma LP; Grunenthal GmbH
• Defendant:  Sandoz Inc.

Infringement of U.S. Patent No. 8,114,383 ("Abuse-Proofed Dosage Form," issued February 14, 2012 following a Paragraph IV certification as part of Sandoz's filing of an ANDA to manufacture a generic version of Purdue Pharma's OxyContin® (controlled release oxycodone hydrochloride, used to treat pain).  View the complaint here.


Written by:

Published In:

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© McDonnell Boehnen Hulbert & Berghoff LLP | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »

All the intelligence you need, in one easy email:

Great! Your first step to building an email digest of JD Supra authors and topics. Log in with LinkedIn so we can start sending your digest...

Sign up for your custom alerts now, using LinkedIn ›

* With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name.